One‐year outcomes of consecutive patients treated by endeavor zotarolimus and resolute zotarolimus stents: The impact of polymer coating in drug‐eluting stent technology

Abstract

The results of this study suggest that the clinical outcome of patients treated by DES differing for the polymer coating only may be different. Polymer coating is a pivotal, probably underrated, component of DES technology which may influence the clinical performance of DES.

Mechanisms and Patterns of Intravascular Ultrasound In-Stent Restenosis Among Bare Metal Stents and First- and Second-Generation Drug-Eluting Stents

“…7,8 This study was approved by the institutional review board, and written informed consent was obtained from all patients.…”

Thrombin‐Induced Platelet‐Fibrin Clot Strength Identified by Thrombelastography

“…Second‐generation DES, including everolimus‐ and zotarolimus‐eluting stents, have been developed with improved stent polymer biocompatibility that reduce local inflammatory responses . However, inconsistent rates of ISR are still reported despite the growing use of second‐generation DES suggesting an involvement of other mechanisms …”

Resolute Integrity drug eluting stent safety and efficacy for the treatment of coronary artery disease

“…In the RESOLUTE All-Comers trial, the rate of definite ST was significantly higher in the R-ZES group (1.2%) than in the XV-EES group (0.3%, P = 0.01) at 12 months, which was primarily related to a higher rate of definite ST at 30 days in the zotarolimus-stent group than in the everolimus-stent group. 23 Talarico et al, 28 reported a significantly higher number of definite, probable, and possible cases of ST in the E-ZES group (with one case of definite ST), while no definite or probable …”

“…Lesion complexity is another factor that was described in some studies, 8,20,22,23,25 including the one by Talarico et al 28 that described that patients treated with the R-ZES had longer and more complex lesions, with higher rate of ACC/AHA B2/C, 30 and higher SYNTAX™ score 40,41 and bifurcated lesions. The outcome in bifurcation lesions was evaluated in the multicenter Italian registry that evaluated lesions with more than 70% stenosis at a major bifurcation point and a main vessel diameter of more than 2.5 mm.…”

“…Talarico et al (Rome, Italy) 28 conducted an independent study that compared the clinical outcome of patients treated with E-ZES and R-ZES in a total of 467 patients; of these, 233 were treated with E-ZES and 234 with R-ZES. At 12-month follow-up, MACE rate was significantly lower in the R-ZES group compared with E-ZES group (4.2% vs 14.6%; P , 0.01) and, this difference was secondary to nonsignificant lower MI and death rates, as well as significant lower TLR (3.4% vs 10.3%, P , 0.01).…”